Companies › Blueprint Medicines
4 active drug programs in 10 registered trials: 6 Phase 2, 3 Phase 1, 1 Phase 4; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Avapritinib (BLU-285) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 4 | Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 … | Jun 2027 |
| BLU-808 Wild type KIT inhibitor | KIT | Phase 2 | Chronic Inducible Urticaria | Dec 2026 |
| Elenestinib (BLU-263) KIT inhibitor | KIT | Phase 2 | Indolent Systemic Mastocytosis | Sep 2032 |
| BLU-924 (SAR449336) pan-KRAS inhibitor | KRAS | Phase 1 | Advanced Solid Tumor | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06783790 | Avapritinib (BLU-285) | Phase 2 | AML (Acute Myelogenous Leukemia) | Oncology | Dec 2026 |
| NCT04771520 | Avapritinib (BLU-285) | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Dec 2026 |
| NCT06931405 | BLU-808 | Phase 2 | Chronic Inducible Urticaria | Immunology | Dec 2026 |
| NCT06316960 | Avapritinib (BLU-285) | Phase 2 | AML, Childhood | Oncology | Mar 2027 |
| NCT06327685 | Avapritinib (BLU-285) | Phase 1 | Systemic Mastocytosis With an Associated Hematologic Neoplasm | Oncology | Mar 2027 |
| NCT07028073 | Avapritinib (BLU-285) | Phase 1 | Acute Myeloid Leukemia With T(8;21)(Q22;Q22) | Oncology | May 2027 |
| NCT03731260 | Avapritinib (BLU-285) | Phase 2 | Indolent Systemic Mastocytosis | Oncology | Jun 2027 |
| NCT06748001 | Avapritinib (BLU-285) | Phase 4 | Mastocytosis, Systemic | Oncology | Dec 2027 |
| NCT07629960 | BLU-924 (SAR449336) | Phase 1 | Advanced Solid Tumor | Oncology | Sep 2029 |
| NCT04910685 | Elenestinib (BLU-263) | Phase 2 | Indolent Systemic Mastocytosis | Oncology | Sep 2032 |
Genfleet Therapeutics (Shanghai) Deciphera Pharmaceuticals Cogent Biosciences HUYABIO International Ranok Therapeutics (Hangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.